nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—HRH1—atherosclerosis	0.637	1	CbGaD
Zuclopenthixol—CYP2D6—Niacin—atherosclerosis	0.033	0.3	CbGbCtD
Zuclopenthixol—CYP2D6—Simvastatin—atherosclerosis	0.0261	0.237	CbGbCtD
Zuclopenthixol—CYP2D6—Lovastatin—atherosclerosis	0.0255	0.232	CbGbCtD
Zuclopenthixol—CYP2D6—Pravastatin—atherosclerosis	0.0255	0.232	CbGbCtD
Zuclopenthixol—HTR2A—arteriole—atherosclerosis	0.00177	0.251	CbGeAlD
Zuclopenthixol—HTR2A—vein—atherosclerosis	0.00105	0.15	CbGeAlD
Zuclopenthixol—Cetirizine—HRH1—atherosclerosis	0.00105	0.175	CrCbGaD
Zuclopenthixol—Hydroxyzine—HRH1—atherosclerosis	0.000808	0.135	CrCbGaD
Zuclopenthixol—HTR2A—hindlimb—atherosclerosis	0.000701	0.0995	CbGeAlD
Zuclopenthixol—HTR2A—appendage—atherosclerosis	0.000601	0.0853	CbGeAlD
Zuclopenthixol—Arrhythmia—Rosuvastatin—atherosclerosis	0.000588	0.00365	CcSEcCtD
Zuclopenthixol—Eosinophilia—Pravastatin—atherosclerosis	0.000583	0.00363	CcSEcCtD
Zuclopenthixol—Mental disorder—Rosuvastatin—atherosclerosis	0.000577	0.00358	CcSEcCtD
Zuclopenthixol—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.000576	0.00358	CcSEcCtD
Zuclopenthixol—Sweating increased—Pravastatin—atherosclerosis	0.000574	0.00357	CcSEcCtD
Zuclopenthixol—Jaundice—Simvastatin—atherosclerosis	0.000566	0.00352	CcSEcCtD
Zuclopenthixol—Flatulence—Rosuvastatin—atherosclerosis	0.000565	0.00351	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Niacin—atherosclerosis	0.000551	0.00343	CcSEcCtD
Zuclopenthixol—Dysuria—Pravastatin—atherosclerosis	0.000551	0.00342	CcSEcCtD
Zuclopenthixol—Erectile dysfunction—Pravastatin—atherosclerosis	0.000543	0.00337	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Ezetimibe—atherosclerosis	0.000539	0.00335	CcSEcCtD
Zuclopenthixol—Photosensitivity reaction—Pravastatin—atherosclerosis	0.000538	0.00334	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Ezetimibe—atherosclerosis	0.000538	0.00334	CcSEcCtD
Zuclopenthixol—Weight increased—Pravastatin—atherosclerosis	0.000536	0.00333	CcSEcCtD
Zuclopenthixol—Weight decreased—Pravastatin—atherosclerosis	0.000533	0.00331	CcSEcCtD
Zuclopenthixol—Jaundice—Niacin—atherosclerosis	0.00052	0.00323	CcSEcCtD
Zuclopenthixol—Jaundice—Pravastatin—atherosclerosis	0.000512	0.00318	CcSEcCtD
Zuclopenthixol—Sweating—Niacin—atherosclerosis	0.000512	0.00318	CcSEcCtD
Zuclopenthixol—Angiopathy—Ezetimibe—atherosclerosis	0.000496	0.00308	CcSEcCtD
Zuclopenthixol—Immune system disorder—Ezetimibe—atherosclerosis	0.000494	0.00307	CcSEcCtD
Zuclopenthixol—Myalgia—Rosuvastatin—atherosclerosis	0.000488	0.00303	CcSEcCtD
Zuclopenthixol—Mental disorder—Ezetimibe—atherosclerosis	0.000479	0.00298	CcSEcCtD
Zuclopenthixol—Flatulence—Lovastatin—atherosclerosis	0.000478	0.00297	CcSEcCtD
Zuclopenthixol—Malnutrition—Ezetimibe—atherosclerosis	0.000476	0.00296	CcSEcCtD
Zuclopenthixol—Erythema—Ezetimibe—atherosclerosis	0.000476	0.00296	CcSEcCtD
Zuclopenthixol—Oedema peripheral—Niacin—atherosclerosis	0.000472	0.00293	CcSEcCtD
Zuclopenthixol—Flatulence—Ezetimibe—atherosclerosis	0.000469	0.00292	CcSEcCtD
Zuclopenthixol—Visual impairment—Niacin—atherosclerosis	0.000462	0.00287	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000459	0.00285	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000458	0.00284	CcSEcCtD
Zuclopenthixol—Vision blurred—Lovastatin—atherosclerosis	0.000458	0.00284	CcSEcCtD
Zuclopenthixol—Mental disorder—Simvastatin—atherosclerosis	0.000457	0.00284	CcSEcCtD
Zuclopenthixol—Tremor—Lovastatin—atherosclerosis	0.000455	0.00283	CcSEcCtD
Zuclopenthixol—Visual impairment—Pravastatin—atherosclerosis	0.000455	0.00282	CcSEcCtD
Zuclopenthixol—Erythema—Simvastatin—atherosclerosis	0.000454	0.00282	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Lovastatin—atherosclerosis	0.000451	0.0028	CcSEcCtD
Zuclopenthixol—Eye disorder—Niacin—atherosclerosis	0.000448	0.00278	CcSEcCtD
Zuclopenthixol—Flatulence—Simvastatin—atherosclerosis	0.000448	0.00278	CcSEcCtD
Zuclopenthixol—Tinnitus—Niacin—atherosclerosis	0.000447	0.00278	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000442	0.00275	CcSEcCtD
Zuclopenthixol—Tinnitus—Pravastatin—atherosclerosis	0.00044	0.00273	CcSEcCtD
Zuclopenthixol—Malaise—Lovastatin—atherosclerosis	0.000438	0.00272	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Pravastatin—atherosclerosis	0.000438	0.00272	CcSEcCtD
Zuclopenthixol—Vertigo—Lovastatin—atherosclerosis	0.000436	0.00271	CcSEcCtD
Zuclopenthixol—Angiopathy—Niacin—atherosclerosis	0.000435	0.0027	CcSEcCtD
Zuclopenthixol—Leukopenia—Lovastatin—atherosclerosis	0.000435	0.0027	CcSEcCtD
Zuclopenthixol—HTR2A—artery—atherosclerosis	0.000429	0.061	CbGeAlD
Zuclopenthixol—Malaise—Ezetimibe—atherosclerosis	0.000429	0.00267	CcSEcCtD
Zuclopenthixol—Vision blurred—Simvastatin—atherosclerosis	0.000428	0.00266	CcSEcCtD
Zuclopenthixol—Arrhythmia—Niacin—atherosclerosis	0.000428	0.00266	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000426	0.00265	CcSEcCtD
Zuclopenthixol—Tremor—Simvastatin—atherosclerosis	0.000426	0.00264	CcSEcCtD
Zuclopenthixol—Insomnia—Rosuvastatin—atherosclerosis	0.000423	0.00263	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Simvastatin—atherosclerosis	0.000421	0.00262	CcSEcCtD
Zuclopenthixol—Arrhythmia—Pravastatin—atherosclerosis	0.000421	0.00262	CcSEcCtD
Zuclopenthixol—Palpitations—Ezetimibe—atherosclerosis	0.000421	0.00262	CcSEcCtD
Zuclopenthixol—Paraesthesia—Rosuvastatin—atherosclerosis	0.00042	0.00261	CcSEcCtD
Zuclopenthixol—Erythema—Niacin—atherosclerosis	0.000417	0.00259	CcSEcCtD
Zuclopenthixol—Malnutrition—Niacin—atherosclerosis	0.000417	0.00259	CcSEcCtD
Zuclopenthixol—Myalgia—Lovastatin—atherosclerosis	0.000413	0.00257	CcSEcCtD
Zuclopenthixol—Anxiety—Lovastatin—atherosclerosis	0.000412	0.00256	CcSEcCtD
Zuclopenthixol—Dyspepsia—Rosuvastatin—atherosclerosis	0.000412	0.00256	CcSEcCtD
Zuclopenthixol—Hypertension—Ezetimibe—atherosclerosis	0.000411	0.00255	CcSEcCtD
Zuclopenthixol—Flatulence—Niacin—atherosclerosis	0.000411	0.00255	CcSEcCtD
Zuclopenthixol—Malaise—Simvastatin—atherosclerosis	0.00041	0.00254	CcSEcCtD
Zuclopenthixol—Tension—Niacin—atherosclerosis	0.000409	0.00254	CcSEcCtD
Zuclopenthixol—Discomfort—Lovastatin—atherosclerosis	0.000408	0.00254	CcSEcCtD
Zuclopenthixol—Vertigo—Simvastatin—atherosclerosis	0.000408	0.00254	CcSEcCtD
Zuclopenthixol—Leukopenia—Simvastatin—atherosclerosis	0.000407	0.00253	CcSEcCtD
Zuclopenthixol—Myalgia—Ezetimibe—atherosclerosis	0.000405	0.00252	CcSEcCtD
Zuclopenthixol—Nervousness—Niacin—atherosclerosis	0.000405	0.00252	CcSEcCtD
Zuclopenthixol—Flatulence—Pravastatin—atherosclerosis	0.000405	0.00251	CcSEcCtD
Zuclopenthixol—Dry mouth—Lovastatin—atherosclerosis	0.000404	0.00251	CcSEcCtD
Zuclopenthixol—Tension—Pravastatin—atherosclerosis	0.000403	0.0025	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000403	0.0025	CcSEcCtD
Zuclopenthixol—Discomfort—Ezetimibe—atherosclerosis	0.000401	0.00249	CcSEcCtD
Zuclopenthixol—Trazodone—HRH1—atherosclerosis	0.0004	0.067	CrCbGaD
Zuclopenthixol—Constipation—Rosuvastatin—atherosclerosis	0.0004	0.00248	CcSEcCtD
Zuclopenthixol—Pain—Rosuvastatin—atherosclerosis	0.0004	0.00248	CcSEcCtD
Zuclopenthixol—Nervousness—Pravastatin—atherosclerosis	0.000399	0.00248	CcSEcCtD
Zuclopenthixol—Dry mouth—Ezetimibe—atherosclerosis	0.000397	0.00246	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Lovastatin—atherosclerosis	0.000396	0.00246	CcSEcCtD
Zuclopenthixol—Vision blurred—Niacin—atherosclerosis	0.000393	0.00244	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000389	0.00242	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Lovastatin—atherosclerosis	0.000388	0.00241	CcSEcCtD
Zuclopenthixol—Vision blurred—Pravastatin—atherosclerosis	0.000387	0.0024	CcSEcCtD
Zuclopenthixol—Myalgia—Simvastatin—atherosclerosis	0.000387	0.0024	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000385	0.00239	CcSEcCtD
Zuclopenthixol—Anxiety—Simvastatin—atherosclerosis	0.000385	0.00239	CcSEcCtD
Zuclopenthixol—Tremor—Pravastatin—atherosclerosis	0.000385	0.00239	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000382	0.00238	CcSEcCtD
Zuclopenthixol—Discomfort—Simvastatin—atherosclerosis	0.000382	0.00237	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Ezetimibe—atherosclerosis	0.000381	0.00237	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Pravastatin—atherosclerosis	0.000381	0.00237	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000381	0.00236	CcSEcCtD
Zuclopenthixol—Anorexia—Lovastatin—atherosclerosis	0.000378	0.00235	CcSEcCtD
Zuclopenthixol—Skin disorder—Ezetimibe—atherosclerosis	0.000378	0.00235	CcSEcCtD
Zuclopenthixol—Thiothixene—HRH1—atherosclerosis	0.000375	0.0628	CrCbGaD
Zuclopenthixol—Vertigo—Niacin—atherosclerosis	0.000375	0.00233	CcSEcCtD
Zuclopenthixol—Syncope—Niacin—atherosclerosis	0.000374	0.00232	CcSEcCtD
Zuclopenthixol—Leukopenia—Niacin—atherosclerosis	0.000373	0.00232	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Simvastatin—atherosclerosis	0.000371	0.0023	CcSEcCtD
Zuclopenthixol—Malaise—Pravastatin—atherosclerosis	0.00037	0.0023	CcSEcCtD
Zuclopenthixol—Abdominal pain—Rosuvastatin—atherosclerosis	0.00037	0.0023	CcSEcCtD
Zuclopenthixol—Vertigo—Pravastatin—atherosclerosis	0.000369	0.00229	CcSEcCtD
Zuclopenthixol—Palpitations—Niacin—atherosclerosis	0.000369	0.00229	CcSEcCtD
Zuclopenthixol—Leukopenia—Pravastatin—atherosclerosis	0.000368	0.00228	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Niacin—atherosclerosis	0.000367	0.00228	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Simvastatin—atherosclerosis	0.000363	0.00226	CcSEcCtD
Zuclopenthixol—HTR2A—endothelium—atherosclerosis	0.000363	0.0515	CbGeAlD
Zuclopenthixol—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000361	0.00224	CcSEcCtD
Zuclopenthixol—Insomnia—Lovastatin—atherosclerosis	0.000358	0.00223	CcSEcCtD
Zuclopenthixol—Prochlorperazine—HRH1—atherosclerosis	0.000358	0.06	CrCbGaD
Zuclopenthixol—Paraesthesia—Lovastatin—atherosclerosis	0.000356	0.00221	CcSEcCtD
Zuclopenthixol—Myalgia—Niacin—atherosclerosis	0.000355	0.00221	CcSEcCtD
Zuclopenthixol—Hypertension—Pravastatin—atherosclerosis	0.000355	0.0022	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000354	0.0022	CcSEcCtD
Zuclopenthixol—Anorexia—Simvastatin—atherosclerosis	0.000353	0.0022	CcSEcCtD
Zuclopenthixol—Dyspnoea—Lovastatin—atherosclerosis	0.000353	0.0022	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000353	0.00219	CcSEcCtD
Zuclopenthixol—Insomnia—Ezetimibe—atherosclerosis	0.000352	0.00218	CcSEcCtD
Zuclopenthixol—Myalgia—Pravastatin—atherosclerosis	0.00035	0.00217	CcSEcCtD
Zuclopenthixol—Paraesthesia—Ezetimibe—atherosclerosis	0.000349	0.00217	CcSEcCtD
Zuclopenthixol—Dyspepsia—Lovastatin—atherosclerosis	0.000349	0.00217	CcSEcCtD
Zuclopenthixol—Anxiety—Pravastatin—atherosclerosis	0.000348	0.00216	CcSEcCtD
Zuclopenthixol—Dry mouth—Niacin—atherosclerosis	0.000347	0.00216	CcSEcCtD
Zuclopenthixol—Dyspnoea—Ezetimibe—atherosclerosis	0.000347	0.00215	CcSEcCtD
Zuclopenthixol—Discomfort—Pravastatin—atherosclerosis	0.000345	0.00215	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000345	0.00214	CcSEcCtD
Zuclopenthixol—Decreased appetite—Lovastatin—atherosclerosis	0.000344	0.00214	CcSEcCtD
Zuclopenthixol—Dyspepsia—Ezetimibe—atherosclerosis	0.000342	0.00213	CcSEcCtD
Zuclopenthixol—Fatigue—Lovastatin—atherosclerosis	0.000342	0.00212	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Niacin—atherosclerosis	0.00034	0.00211	CcSEcCtD
Zuclopenthixol—Pain—Lovastatin—atherosclerosis	0.000339	0.00211	CcSEcCtD
Zuclopenthixol—Constipation—Lovastatin—atherosclerosis	0.000339	0.00211	CcSEcCtD
Zuclopenthixol—Decreased appetite—Ezetimibe—atherosclerosis	0.000338	0.0021	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000338	0.0021	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000336	0.00209	CcSEcCtD
Zuclopenthixol—Asthenia—Rosuvastatin—atherosclerosis	0.000335	0.00208	CcSEcCtD
Zuclopenthixol—Insomnia—Simvastatin—atherosclerosis	0.000335	0.00208	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Pravastatin—atherosclerosis	0.000335	0.00208	CcSEcCtD
Zuclopenthixol—Fatigue—Ezetimibe—atherosclerosis	0.000335	0.00208	CcSEcCtD
Zuclopenthixol—Shock—Niacin—atherosclerosis	0.000335	0.00208	CcSEcCtD
Zuclopenthixol—HTR2A—blood vessel—atherosclerosis	0.000335	0.0475	CbGeAlD
Zuclopenthixol—Paraesthesia—Simvastatin—atherosclerosis	0.000333	0.00207	CcSEcCtD
Zuclopenthixol—Pain—Ezetimibe—atherosclerosis	0.000332	0.00207	CcSEcCtD
Zuclopenthixol—Constipation—Ezetimibe—atherosclerosis	0.000332	0.00207	CcSEcCtD
Zuclopenthixol—Tachycardia—Niacin—atherosclerosis	0.000332	0.00206	CcSEcCtD
Zuclopenthixol—Pruritus—Rosuvastatin—atherosclerosis	0.000331	0.00206	CcSEcCtD
Zuclopenthixol—Skin disorder—Niacin—atherosclerosis	0.000331	0.00205	CcSEcCtD
Zuclopenthixol—Dyspnoea—Simvastatin—atherosclerosis	0.00033	0.00205	CcSEcCtD
Zuclopenthixol—Amoxapine—HRH1—atherosclerosis	0.000329	0.0552	CrCbGaD
Zuclopenthixol—Hyperhidrosis—Niacin—atherosclerosis	0.000329	0.00204	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Pravastatin—atherosclerosis	0.000328	0.00204	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Lovastatin—atherosclerosis	0.000327	0.00203	CcSEcCtD
Zuclopenthixol—Dyspepsia—Simvastatin—atherosclerosis	0.000326	0.00203	CcSEcCtD
Zuclopenthixol—Anorexia—Niacin—atherosclerosis	0.000324	0.00202	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000324	0.00201	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Pravastatin—atherosclerosis	0.000324	0.00201	CcSEcCtD
Zuclopenthixol—Fluphenazine—HRH1—atherosclerosis	0.000324	0.0543	CrCbGaD
Zuclopenthixol—Decreased appetite—Simvastatin—atherosclerosis	0.000322	0.002	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Ezetimibe—atherosclerosis	0.00032	0.00199	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00032	0.00199	CcSEcCtD
Zuclopenthixol—Diarrhoea—Rosuvastatin—atherosclerosis	0.00032	0.00199	CcSEcCtD
Zuclopenthixol—Fatigue—Simvastatin—atherosclerosis	0.00032	0.00199	CcSEcCtD
Zuclopenthixol—Anorexia—Pravastatin—atherosclerosis	0.000319	0.00198	CcSEcCtD
Zuclopenthixol—Hypotension—Niacin—atherosclerosis	0.000318	0.00198	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000318	0.00197	CcSEcCtD
Zuclopenthixol—Pain—Simvastatin—atherosclerosis	0.000317	0.00197	CcSEcCtD
Zuclopenthixol—Constipation—Simvastatin—atherosclerosis	0.000317	0.00197	CcSEcCtD
Zuclopenthixol—Abdominal pain—Lovastatin—atherosclerosis	0.000313	0.00195	CcSEcCtD
Zuclopenthixol—Body temperature increased—Lovastatin—atherosclerosis	0.000313	0.00195	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00031	0.00193	CcSEcCtD
Zuclopenthixol—Dizziness—Rosuvastatin—atherosclerosis	0.000309	0.00192	CcSEcCtD
Zuclopenthixol—Insomnia—Niacin—atherosclerosis	0.000308	0.00191	CcSEcCtD
Zuclopenthixol—Abdominal pain—Ezetimibe—atherosclerosis	0.000307	0.00191	CcSEcCtD
Zuclopenthixol—Body temperature increased—Ezetimibe—atherosclerosis	0.000307	0.00191	CcSEcCtD
Zuclopenthixol—Paraesthesia—Niacin—atherosclerosis	0.000306	0.0019	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Simvastatin—atherosclerosis	0.000305	0.0019	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000305	0.0019	CcSEcCtD
Zuclopenthixol—Dyspnoea—Niacin—atherosclerosis	0.000303	0.00189	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000303	0.00188	CcSEcCtD
Zuclopenthixol—Insomnia—Pravastatin—atherosclerosis	0.000303	0.00188	CcSEcCtD
Zuclopenthixol—Somnolence—Niacin—atherosclerosis	0.000303	0.00188	CcSEcCtD
Zuclopenthixol—Paraesthesia—Pravastatin—atherosclerosis	0.000301	0.00187	CcSEcCtD
Zuclopenthixol—Dyspepsia—Niacin—atherosclerosis	0.0003	0.00186	CcSEcCtD
Zuclopenthixol—Dyspnoea—Pravastatin—atherosclerosis	0.000299	0.00186	CcSEcCtD
Zuclopenthixol—Decreased appetite—Niacin—atherosclerosis	0.000296	0.00184	CcSEcCtD
Zuclopenthixol—Dyspepsia—Pravastatin—atherosclerosis	0.000295	0.00183	CcSEcCtD
Zuclopenthixol—Chlorprothixene—HRH1—atherosclerosis	0.000295	0.0494	CrCbGaD
Zuclopenthixol—Rash—Rosuvastatin—atherosclerosis	0.000295	0.00183	CcSEcCtD
Zuclopenthixol—Dermatitis—Rosuvastatin—atherosclerosis	0.000295	0.00183	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Niacin—atherosclerosis	0.000294	0.00183	CcSEcCtD
Zuclopenthixol—Abdominal pain—Simvastatin—atherosclerosis	0.000293	0.00182	CcSEcCtD
Zuclopenthixol—Body temperature increased—Simvastatin—atherosclerosis	0.000293	0.00182	CcSEcCtD
Zuclopenthixol—Headache—Rosuvastatin—atherosclerosis	0.000293	0.00182	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Lovastatin—atherosclerosis	0.000292	0.00181	CcSEcCtD
Zuclopenthixol—Decreased appetite—Pravastatin—atherosclerosis	0.000291	0.00181	CcSEcCtD
Zuclopenthixol—Pain—Niacin—atherosclerosis	0.000291	0.00181	CcSEcCtD
Zuclopenthixol—Fatigue—Pravastatin—atherosclerosis	0.000289	0.0018	CcSEcCtD
Zuclopenthixol—Pain—Pravastatin—atherosclerosis	0.000287	0.00178	CcSEcCtD
Zuclopenthixol—Constipation—Pravastatin—atherosclerosis	0.000287	0.00178	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Ezetimibe—atherosclerosis	0.000286	0.00178	CcSEcCtD
Zuclopenthixol—Asthenia—Lovastatin—atherosclerosis	0.000284	0.00177	CcSEcCtD
Zuclopenthixol—Pruritus—Lovastatin—atherosclerosis	0.00028	0.00174	CcSEcCtD
Zuclopenthixol—Thioridazine—HRH1—atherosclerosis	0.000279	0.0468	CrCbGaD
Zuclopenthixol—Asthenia—Ezetimibe—atherosclerosis	0.000279	0.00173	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Niacin—atherosclerosis	0.000278	0.00173	CcSEcCtD
Zuclopenthixol—Nausea—Rosuvastatin—atherosclerosis	0.000278	0.00173	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Pravastatin—atherosclerosis	0.000276	0.00172	CcSEcCtD
Zuclopenthixol—Pruritus—Ezetimibe—atherosclerosis	0.000275	0.00171	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000274	0.0017	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Simvastatin—atherosclerosis	0.000273	0.0017	CcSEcCtD
Zuclopenthixol—Diarrhoea—Lovastatin—atherosclerosis	0.000271	0.00168	CcSEcCtD
Zuclopenthixol—Abdominal pain—Niacin—atherosclerosis	0.000269	0.00167	CcSEcCtD
Zuclopenthixol—Body temperature increased—Niacin—atherosclerosis	0.000269	0.00167	CcSEcCtD
Zuclopenthixol—Asthenia—Simvastatin—atherosclerosis	0.000266	0.00165	CcSEcCtD
Zuclopenthixol—Diarrhoea—Ezetimibe—atherosclerosis	0.000266	0.00165	CcSEcCtD
Zuclopenthixol—Abdominal pain—Pravastatin—atherosclerosis	0.000265	0.00165	CcSEcCtD
Zuclopenthixol—Body temperature increased—Pravastatin—atherosclerosis	0.000265	0.00165	CcSEcCtD
Zuclopenthixol—Pruritus—Simvastatin—atherosclerosis	0.000262	0.00163	CcSEcCtD
Zuclopenthixol—Dizziness—Lovastatin—atherosclerosis	0.000262	0.00163	CcSEcCtD
Zuclopenthixol—Trifluoperazine—HRH1—atherosclerosis	0.000259	0.0434	CrCbGaD
Zuclopenthixol—Loxapine—HRH1—atherosclerosis	0.000257	0.0431	CrCbGaD
Zuclopenthixol—Dizziness—Ezetimibe—atherosclerosis	0.000257	0.0016	CcSEcCtD
Zuclopenthixol—Perphenazine—HRH1—atherosclerosis	0.000256	0.0429	CrCbGaD
Zuclopenthixol—Diarrhoea—Simvastatin—atherosclerosis	0.000254	0.00158	CcSEcCtD
Zuclopenthixol—Vomiting—Lovastatin—atherosclerosis	0.000252	0.00157	CcSEcCtD
Zuclopenthixol—Quetiapine—HRH1—atherosclerosis	0.000251	0.0421	CrCbGaD
Zuclopenthixol—Hypersensitivity—Niacin—atherosclerosis	0.000251	0.00156	CcSEcCtD
Zuclopenthixol—Rash—Lovastatin—atherosclerosis	0.00025	0.00155	CcSEcCtD
Zuclopenthixol—Dermatitis—Lovastatin—atherosclerosis	0.00025	0.00155	CcSEcCtD
Zuclopenthixol—Headache—Lovastatin—atherosclerosis	0.000248	0.00154	CcSEcCtD
Zuclopenthixol—Vomiting—Ezetimibe—atherosclerosis	0.000247	0.00154	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Pravastatin—atherosclerosis	0.000247	0.00153	CcSEcCtD
Zuclopenthixol—Dizziness—Simvastatin—atherosclerosis	0.000245	0.00152	CcSEcCtD
Zuclopenthixol—Rash—Ezetimibe—atherosclerosis	0.000245	0.00152	CcSEcCtD
Zuclopenthixol—Dermatitis—Ezetimibe—atherosclerosis	0.000245	0.00152	CcSEcCtD
Zuclopenthixol—Asthenia—Niacin—atherosclerosis	0.000244	0.00152	CcSEcCtD
Zuclopenthixol—Headache—Ezetimibe—atherosclerosis	0.000243	0.00151	CcSEcCtD
Zuclopenthixol—Pruritus—Niacin—atherosclerosis	0.000241	0.0015	CcSEcCtD
Zuclopenthixol—Asthenia—Pravastatin—atherosclerosis	0.00024	0.00149	CcSEcCtD
Zuclopenthixol—Pruritus—Pravastatin—atherosclerosis	0.000237	0.00147	CcSEcCtD
Zuclopenthixol—Vomiting—Simvastatin—atherosclerosis	0.000236	0.00146	CcSEcCtD
Zuclopenthixol—Nausea—Lovastatin—atherosclerosis	0.000235	0.00146	CcSEcCtD
Zuclopenthixol—Rash—Simvastatin—atherosclerosis	0.000234	0.00145	CcSEcCtD
Zuclopenthixol—Dermatitis—Simvastatin—atherosclerosis	0.000233	0.00145	CcSEcCtD
Zuclopenthixol—Diarrhoea—Niacin—atherosclerosis	0.000233	0.00145	CcSEcCtD
Zuclopenthixol—Headache—Simvastatin—atherosclerosis	0.000232	0.00144	CcSEcCtD
Zuclopenthixol—Nausea—Ezetimibe—atherosclerosis	0.000231	0.00143	CcSEcCtD
Zuclopenthixol—ADRA1A—cardiovascular system—atherosclerosis	0.000231	0.0328	CbGeAlD
Zuclopenthixol—Diarrhoea—Pravastatin—atherosclerosis	0.000229	0.00142	CcSEcCtD
Zuclopenthixol—Dizziness—Niacin—atherosclerosis	0.000225	0.0014	CcSEcCtD
Zuclopenthixol—Dizziness—Pravastatin—atherosclerosis	0.000222	0.00138	CcSEcCtD
Zuclopenthixol—Nausea—Simvastatin—atherosclerosis	0.00022	0.00137	CcSEcCtD
Zuclopenthixol—Vomiting—Niacin—atherosclerosis	0.000216	0.00134	CcSEcCtD
Zuclopenthixol—Clozapine—HRH1—atherosclerosis	0.000216	0.0362	CrCbGaD
Zuclopenthixol—Rash—Niacin—atherosclerosis	0.000215	0.00133	CcSEcCtD
Zuclopenthixol—Dermatitis—Niacin—atherosclerosis	0.000214	0.00133	CcSEcCtD
Zuclopenthixol—Headache—Niacin—atherosclerosis	0.000213	0.00132	CcSEcCtD
Zuclopenthixol—Vomiting—Pravastatin—atherosclerosis	0.000213	0.00132	CcSEcCtD
Zuclopenthixol—Rash—Pravastatin—atherosclerosis	0.000211	0.00131	CcSEcCtD
Zuclopenthixol—Dermatitis—Pravastatin—atherosclerosis	0.000211	0.00131	CcSEcCtD
Zuclopenthixol—Headache—Pravastatin—atherosclerosis	0.00021	0.0013	CcSEcCtD
Zuclopenthixol—HRH1—connective tissue—atherosclerosis	0.000205	0.0292	CbGeAlD
Zuclopenthixol—ADRA1A—adipose tissue—atherosclerosis	0.000204	0.0289	CbGeAlD
Zuclopenthixol—Chlorpromazine—HRH1—atherosclerosis	0.000203	0.0341	CrCbGaD
Zuclopenthixol—Nausea—Niacin—atherosclerosis	0.000202	0.00126	CcSEcCtD
Zuclopenthixol—ADRA2A—connective tissue—atherosclerosis	0.000202	0.0286	CbGeAlD
Zuclopenthixol—Nausea—Pravastatin—atherosclerosis	0.000199	0.00124	CcSEcCtD
Zuclopenthixol—HTR2A—connective tissue—atherosclerosis	0.000172	0.0244	CbGeAlD
Zuclopenthixol—HRH1—adipose tissue—atherosclerosis	0.000158	0.0224	CbGeAlD
Zuclopenthixol—ADRA2A—adipose tissue—atherosclerosis	0.000155	0.022	CbGeAlD
Zuclopenthixol—HTR2A—cardiovascular system—atherosclerosis	0.000149	0.0212	CbGeAlD
Zuclopenthixol—ADRA1A—liver—atherosclerosis	0.000143	0.0203	CbGeAlD
Zuclopenthixol—HTR2A—liver—atherosclerosis	9.23e-05	0.0131	CbGeAlD
Zuclopenthixol—Thioproperazine—ALB—atherosclerosis	8.79e-05	0.0147	CrCbGaD
Zuclopenthixol—Pipotiazine—ALB—atherosclerosis	8.65e-05	0.0145	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—atherosclerosis	8.65e-05	0.0145	CrCbGaD
Zuclopenthixol—CYP2D6—liver—atherosclerosis	8.41e-05	0.0119	CbGeAlD
Zuclopenthixol—Chlorpromazine—ALB—atherosclerosis	4.69e-05	0.00786	CrCbGaD
Zuclopenthixol—DRD5—Signaling Pathways—MMP9—atherosclerosis	9.97e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	9.97e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL5—atherosclerosis	9.97e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CG—atherosclerosis	9.95e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	9.93e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—LPL—atherosclerosis	9.93e-06	0.000126	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMGCR—atherosclerosis	9.9e-06	0.000125	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—NFKB1—atherosclerosis	9.87e-06	0.000125	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	9.86e-06	0.000125	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	9.78e-06	0.000124	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—LPL—atherosclerosis	9.77e-06	0.000124	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—LPL—atherosclerosis	9.75e-06	0.000123	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MAPK8—atherosclerosis	9.7e-06	0.000123	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—AKT1—atherosclerosis	9.67e-06	0.000123	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PRKCG—atherosclerosis	9.66e-06	0.000122	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	9.63e-06	0.000122	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NOS3—atherosclerosis	9.6e-06	0.000122	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	9.59e-06	0.000121	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—MTHFR—atherosclerosis	9.57e-06	0.000121	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—LPL—atherosclerosis	9.57e-06	0.000121	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—MAPK3—atherosclerosis	9.53e-06	0.000121	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	9.5e-06	0.00012	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PRKCG—atherosclerosis	9.48e-06	0.00012	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—INS—atherosclerosis	9.42e-06	0.000119	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SPP1—atherosclerosis	9.41e-06	0.000119	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARA—atherosclerosis	9.39e-06	0.000119	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	9.36e-06	0.000119	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOB—atherosclerosis	9.31e-06	0.000118	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	9.3e-06	0.000118	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CCL2—atherosclerosis	9.27e-06	0.000117	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SPP1—atherosclerosis	9.25e-06	0.000117	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SPP1—atherosclerosis	9.23e-06	0.000117	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	9.23e-06	0.000117	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	9.21e-06	0.000117	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—CXCL8—atherosclerosis	9.19e-06	0.000116	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	9.16e-06	0.000116	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IGF1—atherosclerosis	9.11e-06	0.000115	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AGT—atherosclerosis	9.09e-06	0.000115	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	9.09e-06	0.000115	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	9.06e-06	0.000115	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	9.02e-06	0.000114	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—VEGFA—atherosclerosis	8.96e-06	0.000113	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—APOE—atherosclerosis	8.91e-06	0.000113	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—LPL—atherosclerosis	8.89e-06	0.000113	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—STAT3—atherosclerosis	8.87e-06	0.000112	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CAV1—atherosclerosis	8.83e-06	0.000112	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ABCA1—atherosclerosis	8.83e-06	0.000112	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—APOA1—atherosclerosis	8.81e-06	0.000112	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PDGFB—atherosclerosis	8.7e-06	0.00011	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SERPINE1—atherosclerosis	8.65e-06	0.00011	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	8.64e-06	0.000109	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	8.56e-06	0.000108	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PDGFB—atherosclerosis	8.54e-06	0.000108	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—CXCL8—atherosclerosis	8.51e-06	0.000108	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AGT—atherosclerosis	8.5e-06	0.000108	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—MAPK3—atherosclerosis	8.47e-06	0.000107	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	8.42e-06	0.000107	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	8.38e-06	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	8.38e-06	0.000106	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AGT—atherosclerosis	8.36e-06	0.000106	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AGT—atherosclerosis	8.34e-06	0.000106	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—LEP—atherosclerosis	8.32e-06	0.000105	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOE—atherosclerosis	8.32e-06	0.000105	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NOS3—atherosclerosis	8.26e-06	0.000105	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CAV1—atherosclerosis	8.25e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—APOA1—atherosclerosis	8.23e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	8.22e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TGFB1—atherosclerosis	8.22e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—LEP—atherosclerosis	8.19e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOE—atherosclerosis	8.19e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AGT—atherosclerosis	8.18e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—LEP—atherosclerosis	8.17e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOE—atherosclerosis	8.17e-06	0.000104	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CAV1—atherosclerosis	8.11e-06	0.000103	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CAV1—atherosclerosis	8.1e-06	0.000103	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—APOA1—atherosclerosis	8.1e-06	0.000103	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL6—atherosclerosis	8.09e-06	0.000102	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—APOA1—atherosclerosis	8.08e-06	0.000102	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CG—atherosclerosis	8.04e-06	0.000102	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—LEP—atherosclerosis	8.02e-06	0.000102	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOE—atherosclerosis	8.02e-06	0.000102	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ESR1—atherosclerosis	7.95e-06	0.000101	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	7.95e-06	0.000101	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	7.93e-06	0.0001	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—F2—atherosclerosis	7.85e-06	9.94e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ESR1—atherosclerosis	7.82e-06	9.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ESR1—atherosclerosis	7.8e-06	9.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	7.79e-06	9.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—atherosclerosis	7.76e-06	9.83e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—F2—atherosclerosis	7.72e-06	9.78e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—F2—atherosclerosis	7.71e-06	9.76e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MMP9—atherosclerosis	7.7e-06	9.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	7.66e-06	9.7e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NFKB1—atherosclerosis	7.62e-06	9.65e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—INS—atherosclerosis	7.61e-06	9.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AGT—atherosclerosis	7.6e-06	9.63e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMOX1—atherosclerosis	7.57e-06	9.59e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—AKT1—atherosclerosis	7.57e-06	9.59e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—F2—atherosclerosis	7.56e-06	9.58e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	7.51e-06	9.51e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK8—atherosclerosis	7.49e-06	9.48e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—AKT1—atherosclerosis	7.47e-06	9.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—LEP—atherosclerosis	7.45e-06	9.44e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOE—atherosclerosis	7.45e-06	9.44e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	7.39e-06	9.36e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	7.38e-06	9.35e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	7.38e-06	9.34e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	7.37e-06	9.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CXCL8—atherosclerosis	7.33e-06	9.28e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOB—atherosclerosis	7.26e-06	9.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	7.24e-06	9.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	7.19e-06	9.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	7.11e-06	9.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—INS—atherosclerosis	7.11e-06	9.01e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	7.08e-06	8.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	7.08e-06	8.96e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	7.06e-06	8.95e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GSTM1—atherosclerosis	7.06e-06	8.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—F2—atherosclerosis	7.03e-06	8.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—INS—atherosclerosis	7e-06	8.86e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCL2—atherosclerosis	7e-06	8.86e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—INS—atherosclerosis	6.98e-06	8.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—ALB—atherosclerosis	6.98e-06	8.84e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL6—atherosclerosis	6.97e-06	8.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	6.93e-06	8.78e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—LPL—atherosclerosis	6.93e-06	8.77e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—atherosclerosis	6.91e-06	8.75e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCL2—atherosclerosis	6.88e-06	8.72e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IGF1—atherosclerosis	6.88e-06	8.71e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCL2—atherosclerosis	6.87e-06	8.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—INS—atherosclerosis	6.85e-06	8.68e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—STAT3—atherosclerosis	6.84e-06	8.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IGF1—atherosclerosis	6.77e-06	8.57e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GPX1—atherosclerosis	6.76e-06	8.56e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IGF1—atherosclerosis	6.75e-06	8.55e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	6.74e-06	8.54e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	6.72e-06	8.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NOS3—atherosclerosis	6.68e-06	8.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	6.63e-06	8.39e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MMP9—atherosclerosis	6.63e-06	8.39e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CD36—atherosclerosis	6.58e-06	8.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NFKB1—atherosclerosis	6.56e-06	8.3e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK3—atherosclerosis	6.54e-06	8.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	6.53e-06	8.27e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK8—atherosclerosis	6.44e-06	8.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	6.44e-06	8.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—atherosclerosis	6.43e-06	8.14e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	6.43e-06	8.14e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	6.41e-06	8.12e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—INS—atherosclerosis	6.37e-06	8.06e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—atherosclerosis	6.34e-06	8.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	6.29e-06	7.97e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	6.26e-06	7.93e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—atherosclerosis	6.24e-06	7.9e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NOS3—atherosclerosis	6.24e-06	7.9e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—atherosclerosis	6.19e-06	7.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	6.16e-06	7.8e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NOS3—atherosclerosis	6.14e-06	7.77e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NOS3—atherosclerosis	6.12e-06	7.75e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARA—atherosclerosis	6.12e-06	7.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTGS2—atherosclerosis	6.11e-06	7.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	6.01e-06	7.61e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—atherosclerosis	5.95e-06	7.54e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AGT—atherosclerosis	5.93e-06	7.51e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—atherosclerosis	5.89e-06	7.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	5.85e-06	7.41e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOE—atherosclerosis	5.81e-06	7.35e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CAV1—atherosclerosis	5.75e-06	7.29e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—APOA1—atherosclerosis	5.74e-06	7.27e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—atherosclerosis	5.71e-06	7.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK3—atherosclerosis	5.63e-06	7.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	5.58e-06	7.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CXCL8—atherosclerosis	5.53e-06	7.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—atherosclerosis	5.46e-06	6.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	5.44e-06	6.89e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CXCL8—atherosclerosis	5.43e-06	6.88e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	5.34e-06	6.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	5.33e-06	6.75e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—atherosclerosis	5.26e-06	6.66e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	5.26e-06	6.66e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	5.25e-06	6.64e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—atherosclerosis	5.24e-06	6.64e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—atherosclerosis	5.18e-06	6.55e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—atherosclerosis	5.16e-06	6.54e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	5.15e-06	6.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	5.07e-06	6.42e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—atherosclerosis	5.06e-06	6.41e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MMP9—atherosclerosis	5e-06	6.34e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—INS—atherosclerosis	4.96e-06	6.28e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	4.95e-06	6.27e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NFKB1—atherosclerosis	4.95e-06	6.27e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MMP9—atherosclerosis	4.92e-06	6.23e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MMP9—atherosclerosis	4.91e-06	6.22e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	4.87e-06	6.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK8—atherosclerosis	4.87e-06	6.16e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NFKB1—atherosclerosis	4.86e-06	6.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—atherosclerosis	4.85e-06	6.15e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	4.82e-06	6.1e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	4.79e-06	6.06e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	4.78e-06	6.06e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—atherosclerosis	4.78e-06	6.05e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK8—atherosclerosis	4.78e-06	6.05e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	4.77e-06	6.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	4.77e-06	6.04e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—atherosclerosis	4.76e-06	6.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	4.71e-06	5.96e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	4.69e-06	5.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	4.68e-06	5.92e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—atherosclerosis	4.55e-06	5.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—atherosclerosis	4.49e-06	5.69e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	4.48e-06	5.67e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—atherosclerosis	4.45e-06	5.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	4.43e-06	5.61e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	4.42e-06	5.6e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—atherosclerosis	4.41e-06	5.59e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—atherosclerosis	4.41e-06	5.59e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—atherosclerosis	4.38e-06	5.54e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—atherosclerosis	4.37e-06	5.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	4.36e-06	5.52e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NOS3—atherosclerosis	4.35e-06	5.51e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	4.34e-06	5.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	4.33e-06	5.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	4.29e-06	5.43e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK3—atherosclerosis	4.25e-06	5.38e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	4.18e-06	5.3e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK3—atherosclerosis	4.17e-06	5.28e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—atherosclerosis	4.12e-06	5.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—atherosclerosis	4.12e-06	5.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	4.09e-06	5.19e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	4.06e-06	5.14e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—atherosclerosis	4.05e-06	5.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	4.02e-06	5.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	3.98e-06	5.04e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.98e-06	5.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	3.97e-06	5.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	3.8e-06	4.82e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—atherosclerosis	3.8e-06	4.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	3.69e-06	4.67e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—atherosclerosis	3.11e-06	3.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—atherosclerosis	3.07e-06	3.89e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—atherosclerosis	3.06e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—atherosclerosis	3.05e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—atherosclerosis	2.99e-06	3.79e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—atherosclerosis	2.87e-06	3.63e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.82e-06	3.57e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—atherosclerosis	2.81e-06	3.56e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—atherosclerosis	2.78e-06	3.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	2.76e-06	3.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	2.57e-06	3.25e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—atherosclerosis	2e-06	2.53e-05	CbGpPWpGaD
